Sugi Predict

Sugi Predict / Targets / EPHX2

EPHX2

Bifunctional epoxide hydrolase 2 · P34913 · EPHX2 on Sugi Atlas →

505,905 patent compounds predicted against EPHX2, 258,921 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30045 SCHEMBL30045 0.57 16/20
Tebufenpyrad Tebufenpyrad (SCHEMBL26848) 0.48 13/20
SCHEMBL11954 SCHEMBL11954 0.59 12/20
SCHEMBL10627 SCHEMBL10627 0.66 10/20
SCHEMBL30349 SCHEMBL30349 0.61 10/20
SCHEMBL45902 SCHEMBL45902 0.57 9/20
SCHEMBL11717 SCHEMBL11717 0.51 9/20
SCHEMBL11774 SCHEMBL11774 0.48 9/20
SCHEMBL60897 SCHEMBL60897 0.45 9/20
SCHEMBL14439 SCHEMBL14439 0.47 8/20
SCHEMBL50331 SCHEMBL50331 0.47 8/20
SCHEMBL58465 SCHEMBL58465 0.43 8/20
SCHEMBL13803 SCHEMBL13803 0.66 7/20
SCHEMBL27182 SCHEMBL27182 0.47 7/20
SCHEMBL41862 SCHEMBL41862 0.44 7/20
SCHEMBL9390 SCHEMBL9390 0.60 6/20
SCHEMBL10378 SCHEMBL10378 0.58 6/20
Acexamic Acid Acexamic Acid (SCHEMBL24435) 0.51 6/20
SCHEMBL58446 SCHEMBL58446 0.45 6/20
SCHEMBL35903 SCHEMBL35903 0.45 6/20

Clinical trials — most relevant to EPHX2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans PHASE4COMPLETED
Effectiveness of Vitamin D in Primary Dysmenorrhoea PHASE3COMPLETED
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) PHASE1/PHASE2RECRUITING
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure PHASE2COMPLETED
Prostaglandin Inhibition for Emphysema PHASE2COMPLETED
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Electrophilic Fatty Acid Derivatives in Asthma PHASE1COMPLETED
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function nanCOMPLETED
Blood Vessel Study nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Eicosanoids in Human Heart Failure nanUNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A nanACTIVE_NOT_RECRUITING
PGE2/IL-22 Pathway in Various Forms of Eczema nanCOMPLETED
Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression nanCOMPLETED
Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL). nanRECRUITING
Genetics and Cardiovascular Reactivity in Young Twins nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Genetic and Environmental Risk Factors Related to Esophageal Cancer nanACTIVE_NOT_RECRUITING
Risk Burden of Lipoprotein Metabolic Gene Haplotypes nanCOMPLETED
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses nanCOMPLETED
Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study nanUNKNOWN
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHX2 binder may also engage these)

ProteinNameSimilarity
P80299 — 1.000 P80299 →
Q6Q2C2 — 1.000 Q6Q2C2 →
P34914 — 0.997 P34914 →
P0DO69 — 0.988 P0DO69 →
P0DO68 — 0.986 P0DO68 →
Q8K370 — 0.985 Q8K370 →
G5EDL5 — 0.984 G5EDL5 →
P0DY82 — 0.984 P0DY82 →
Q7TS68 — 0.984 Q7TS68 →
Q0IIS3 — 0.984 Q0IIS3 →
Q3V1F8 — 0.984 Q3V1F8 →
Q09509 — 0.984 Q09509 →
A0A075D6M1 — 0.984 A0A075D6M1 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 0.984 landscape →
Q6GQ37 — 0.984 Q6GQ37 →
Q9T079 — 0.983 Q9T079 →
Q0J954 — 0.983 Q0J954 →
Q7QBJ0 — 0.983 Q7QBJ0 →
Q94915 — 0.983 Q94915 →
A0A397HK53 — 0.983 A0A397HK53 →
Q7XR46 — 0.983 Q7XR46 →
P93834 — 0.982 P93834 →
SMS Spermine synthase 0.982 landscape →
A0A8F4NUL3 — 0.982 A0A8F4NUL3 →
P0C585 — 0.982 P0C585 →
A0A1D6NER6 — 0.982 A0A1D6NER6 →
P09842 — 0.982 P09842 →
Q8IUF1 — 0.982 Q8IUF1 →
Q9DCN1 — 0.982 Q9DCN1 →
O18391 — 0.982 O18391 →